ClinicalTrials.gg
RecruitingNCT07059871ADUpdated Jan 2, 2026

A Study of Silkworm Pupa Powder Intervention in the Nutritional Status of Patients With Alzheimer's Disease.

An interventional study of Silkworm pupa powder and Placebo in AD - Alzheimer's Disease, Sarcopenia and Asthenia, sponsored by Zhejiang Hospital. Recruiting at 1 site in China. Open to participants aged 50 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-01-02.

Sponsored by Zhejiang Hospital · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Nov 2025; still recruiting 11 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
50 Years to 90 Years
Sex
All
01

Study summary

The goal of this clinical trial is to learn if silkworm pupa powder works to improve the nutritional status of Alzheimer's disease patients. The main questions it aims to answer are:

  • Does silkworm pupa powder evaluate the effectiveness of silkworm pupae in improving sarcopenia, frailty and quality of life in AD patients?
  • Does silkworm pupa powder improve cognitive function in AD patients?

Researchers will compare silkworm pupa powder to a placebo (a look-alike substance that contains no drug) to see if silkworm pupa powder works to improve the nutritional status of Alzheimer's disease patients.

Participants will:

  • Take drug silkworm pupa powder or a placebo every day for 3 months.
  • Visit the clinic once every 4 weeks for checkups and tests.
  • Keep a diary of their daily consumption.
02

Conditions studied

  • AD - Alzheimer's Disease
  • Sarcopenia
  • Asthenia

Keywords

  • Alzheimer Disease
  • Sarcopenia
  • asthenia
  • nutritional status
03

In context

Sarcopenia

1,329 studies on the registry are indexed under Sarcopenia; 420 are open to participants now.

This study's planned enrollment of 200 is above the median of 60 across 855 interventional studies indexed under Sarcopenia.

Browse Sarcopenia studies →

Lead sponsor

Zhejiang Hospital is the lead sponsor of 9 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Meet the diagnostic criteria for probable dementia due to Alzheimer's disease (AD) as defined by the National Institute on Aging and Alzheimer's Association (NIA-AA) (2024).
  • Male or female (without ). Participants aged 50-90 years (inclusive), with an education level of primary school or higher.
  • (MMSE) score: ≤17 for illiterate, ≤20 for primary school education, ≤22 for secondary school education, ≤23 for university education; Clinical Dementia Rating (CDR) global score > 2.0.
  • Activities of Daily Living (ADL) Scale score >0 and ≤40.
  • Nutritional Risk Screening (NRS 2002) score ≥3 at screening/enrollment.
  • Good general health status, (ECOG) Performance Status score ≤3.
  • If currently receiving approved AD treatments (e.g., acetylcholinesterase inhibitors, GV-971, NMDA receptor antagonists), must be on a stable dose for at least 12 weeks prior to baseline, with stable cognitive assessment scores. Treatment-naïve participants for AD are eligible. Unless otherwise specified, all other permitted concomitant medications (non-AD related) must be stable for at least 4 weeks prior to baseline.
  • Availability of a stable, reliable caregiver confirmed by the investigator.
  • Voluntarily participate in the clinical study, fully understand and be informed about the study, and sign the Form (ICF); willing and able to comply with and complete all trial procedures. If the participant, in the investigator's judgment, lacks capacity to consent, consent must be obtained according to local laws, regulations, and customs (or signed by the patient's caregiver under the authorization of the patient's legal guardian). Agrees to provide peripheral blood, stool, and urine samples for biomarker analysis during the study.

Exclusion criteria

Exclusion Criteria:

  • Dementia caused by: vascular dementia; CNS infections (e.g., AIDS, syphilis); Huntington's disease; Parkinson's disease; Lewy body dementia; traumatic brain injury-related dementia; other physical/chemical factors (e.g., drug intoxication, alcohol intoxication, carbon monoxide poisoning); significant systemic diseases (e.g., hepatic encephalopathy, pulmonary encephalopathy, hypoxic encephalopathy); intracranial space-occupying lesions (e.g., subdural hematoma, brain tumor); endocrine disorders (e.g., thyroid disease, adrenal disease); vitamin deficiencies; or dementia due to any other cause.
  • Co-existing diseases, such as multiple sclerosis, polymyositis, myasthenia gravis, Guillain-Barré syndrome, ankylosing spondylitis, rheumatoid arthritis, systemic lupus erythematosus, vitiligo, etc.
  • Severe renal impairment: \<30 mL/min (Cockcroft-Gault formula) or other known severe renal disease; Severe hepatic impairment: or AST >10 times the (ULN), or other known liver diseases such as acute/chronic active hepatitis, cirrhosis, etc.; Acute myocardial infarction or interventional cardiac procedure within 6 months prior to screening; Heart failure ( Class III-IV); Patients with other severe primary neurological, cardiac, pulmonary, hematopoietic, endocrine system diseases, or psychiatric disorders.
  • Suspected or confirmed history of alcohol or drug abuse.
  • ≤3 months.
  • Pregnant or lactating women. Participants of (including male participants engaging in heterosexual intercourse and their female partners of childbearing potential) planning pregnancy or unwilling to use effective from screening initiation until 3 months after discontinuation of the study drug.
  • Known allergy/ to any component of the product(s).
  • Participation in another investigational drug trial within 30 days prior to screening or current participation in any other clinical trial.
  • Presence of any other severe physical or psychiatric illness or laboratory abnormality that may increase the risk associated with study participation or, in the investigator's judgment, makes the patient unsuitable for the study.
  • psychiatric disorders or severe psychiatric symptoms.
  • score >26.
  • ADL Scale score >40.
  • Clinically significant elevation of tumor markers, history of , or patients with tumors of undetermined nature.
  • Significant risk of suicide.
  • Chronic alcohol abuse or substance abuse that may interfere with efficacy evaluation.
  • Intolerance or allergy to the drugs used in this study.
  • Diagnosis of clinically significant cardiovascular or cerebrovascular disease requiring treatment within the past 12 months or current diagnosis.
  • Antibiotic use: a. Continuous use of antibiotics for >10 days within 12 weeks prior to baseline; b. Anticipated need for antibiotic treatment exceeding 10 days during the study. Any other disease (e.g., cardiac, respiratory, renal, gastrointestinal diseases potentially affecting absorption such as gastric cancer, gastric bypass surgery, or recurrent diarrhea) not adequately controlled and stable, or any condition the investigator believes may affect participant safety or interfere with study assessments.
  • Any other clinically significant abnormality in physical examination, vital signs, laboratory tests, or (ECG) that, in the investigator's opinion, warrants further investigation or treatment, or may interfere with study procedures or safety.
  • Participants with inadequately controlled hemorrhagic disorders (including count \<50 x 10\^9/L or [INR] >1.5 for participants not on anticoagulant therapy like warfarin).
  • Any other condition deemed by the investigator to make the participant unsuitable for study participation.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Experimental group

    Silkworm pupa powder, 2 times a day, two packets (12\*2 g) each time, take with warm water, before meals, for three months

    Dietary Supplement: Silkworm pupa powder

  • Placebo comparator
    Control group

    Placebo, 2 sachets (12\*2 g) twice a day, with warm water, before meals, for three months

    Dietary Supplement: Placebo

Interventions

  • Dietary supplementSilkworm pupa powder

    Silkworm pupa powder, 2 times a day, two packets (12\*2 g) each time, take with warm water, before meals, for three months

  • Dietary supplementPlacebo

    Placebo, 2 sachets (12\*2 g) twice a day, with warm water, before meals, for three months

06

What researchers measure

Primary outcomes

  1. Hemoglobin

    Take blood testing and detect hemoglobin levels

    Time frame: The 4th 、8th and 12th week after taking Silkworm

  2. Albumin

    Detect blood albumin levels

    Time frame: The 4th 、8th and 12th week after taking Silkworm pupa powder.

  3. Serum prealbumin

    Detect serum prealbumin levels

    Time frame: The 4th 、8th and 12th week after taking Silkworm pupa powder.

  4. 25-hydroxyvitamin D

    Detect blood 25-hydroxyvitamin D levels

    Time frame: The 4th 、8th and 12th week after taking Silkworm pupa powder.

  5. Alkaline phosphatase

    Detect blood alkaline phosphatase levels

    Time frame: The 4th 、8th and 12th week after taking Silkworm pupa powder.

  6. Parathyroid hormone

    Detect parathyroid hormone levels

    Time frame: The 4th 、8th and 12th week after taking Silkworm pupa powder.

  7. Calcitonin

    Detect calcitonin levels

    Time frame: The 4th 、8th and 12th week after taking Silkworm pupa powder.

  8. Whole abdominal Computerized tomography (CT) scan

    Take the whole abdominal CT scan

    Time frame: The 4th 、8th and 12th week after taking Silkworm pupa powder.

  9. Diagnostic criteria of the 2019 Asian Sarcopenia Working Group

    Evaluate sarcopenia again

    Time frame: The 4th 、8th and 12th week after taking Silkworm pupa powder.

Secondary outcomes

  1. Mini-mental State Examination(MMSE) Scale

    Take the MMSE Scale again

    Time frame: The 4th、8th and 12th week after taking placebo.

  2. Clinical Dementia Rating(CDR) Scale

    Take the CDR Scale again

    Time frame: The 4th 、8th and 12th week after taking placebo.

  3. Eastern Cooperative Oncology Group Score

    Take the ECOG Score again

    Time frame: The 4th 、8th and 12th week after taking placebo.

  4. Head Magnetic Resonance Scan

    Take Head MR again

    Time frame: The 4th 、8th and 12th week after taking placebo.

  5. Amyloid β-protein(Aβ)

    Detect the blood Amyloid β-protein levels, include Aβ42、Aβ40、Aβ40/42

    Time frame: The 4th 、8th and 12th week after taking placebo.

  6. Phosphorylated microtubule-associated protein Tau(P-Tau)

    Detect the Phosphorylated microtubule-associated protein Tau levels, include P-tau181、P-tau 217

    Time frame: The 4th 、8th and 12th week after taking placebo.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — Our research is in the exploratory stage and it is not yet clear what results will be obtained.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07059871
Lead sponsor
Zhejiang Hospital
Responsible party
Sponsor
First posted
Jul 11, 2025
Start date
Nov 23, 2025
Primary completion
Dec 30, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Jan 2, 2026

Study contacts

Song Qiao
Contact
qiaosongicu@163.com
+86-13116727887

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion